Agena Bioscience in the News

Agena Announces MassARRAY^® Technology Selected for Participation in CANCER-ID Consortium

24 July 2018

San Diego, CA, July 24, 2018 – Agena Bioscience, a global provider of molecular testing solutions, announced today that it has been selected for participation in the CANCER-ID Consortium.  Agena’s MassARRAY® System will support mutation detection from liquid biopsy samples as part of the consortium’s key work packages in... Read More

Agena Announces MassARRAY^® Commercial Partnership Agreement With Dian For China Clinical Laboratory Market

10 July 2018

San Diego, CA, July 10, 2018 – Agena Bioscience announced today that it has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics Co., Ltd (“Dian”), one of China’s largest independent medical laboratories provider. The strategic agreement will enable Dian to promote and broadly commercialize Agena’s MassARRAY® System... Read More

GenomeWeb 360Dx: Agena Looks to China for Global Expansion of the MassARRAY Platform

6 June 2018

New York, NY (360DX), June 6, 2018 –  For Agena Bioscience CEO Peter Dansky, expanding a diagnostics company means going where the growth is, and for his firm, China has clearly been the most robust growth opportunity. Agena’s business today largely comprises the former bioscience unit of Sequenom, now... Read More

Agena and Simceredx Announce Strategic Partnership to Develop and Commercialize Companion Diagnostics in China

26 March 2018

San Diego, CA, and Nanjing, JiangSu, March 26, 2018 – Agena Bioscience (Agena) and Simcere Diagnostics (Simceredx), the subsidiary of SIMCERE Pharmaceutical Group, announced today the signing of a strategic partnership agreement focusing on expanding the use of Agena’s MassARRAY® System for companion diagnostics and pharmacogenetic testing in China.... Read More

Agena Bioscience’s Liquid Biopsy Technology Awarded Horizon 2020 Grant by European Union

30 November 2017

San Diego, CA, November 30, 2017 – Agena Bioscience, a global provider of molecular genetic solutions, today announced it has been selected to participate as an innovative technology provider in the ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA) project. The LIMA project has been awarded a EUR... Read More

Agena Bioscience Bolsters MassARRAY Insights™ Reporting Network by Adding N-of-One

5 October 2017

The collaboration will focus on results interpretation for cancer genomics. San Diego, CA, October 5, 2017– Agena Bioscience, a global provider of molecular genetic solutions and N-of-One Inc., a leader in molecular decision support for oncology, have teamed together to provide interpretation of cancer genomic data generated by the... Read More

Highly Sensitive Assessment Of Common Somatic Mutations In Pulmonary Non-Small Cell Carcinoma With the MassARRAY^® System

27 September 2017

San Diego, CA, September 27, 2017 – Agena Bioscience today announced a comparative study published in PLOS ONE highlighting the use of its mass spectrometry-based platform and new, highly sensitive iPLEX® HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung... Read More

Agena Bioscience Announces Molecular Health As The First Interpretation Software Provider For MassARRAY Insights™

19 September 2017

MassARRAY Insights providers will aid in results interpretation San Diego, CA, September 19, 2017– Agena Bioscience, a global provider of molecular genetic solutions and Molecular Health, a leader in cloud-based decision support technology for precision medicine, have entered into a strategic partnership, whereby Molecular Health Guide® (MH Guide) analysis... Read More

Intermountain Precision Genomics Launches Antidepressant PGx Panels Developed on Agena MassARRAY^®

15 September 2017

NEW YORK, Sept 15, 2017 – Intermountain Precision Genomics’ RxMatch Antidepressant Panel, announced last week, is the lab’s first pharmacogenomics test intended to help physicians use DNA to find the right antidepressants to prescribe to patients. It is also the initial step in a strategy to grow beyond precision... Read More

MassARRAY^® System Selected for Illinois State Cystic Fibrosis Screening of Newborns

1 August 2017

San Diego, CA, August 2, 2017– Agena Bioscience has entered into a 3-year agreement with the Illinois Department of Public Health (IDPH) which will deploy Agena’s MassARRAY System for Cystic Fibrosis (CF) testing as part of the state’s newborn screening program. In 2008, the state of Illinois announced the... Read More